키나아제 저해제 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2034년)

Kinase Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

US $ 5,795 ￦ 8,615,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,795 ￦ 13,075,000

PDF (Multi-user License)

PDF 보고서를 동일 부서 5명이 이용할 수 있는 라이선스입니다. 텍스트 등의 Copy & Paste가 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 11,795 ￦ 17,535,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

키나아제 저해제 시장 - 조사 범위

TMR의 조사 리포트 '세계의 키나아제 저해제 시장'은 2024-2034년의 예측 기간에 시장의 지표에 대한 귀중한 인사이트를 얻기 위해 과거뿐만 아니라 현재의 성장 동향과 기회를 조사했습니다. 이 보고서에서는 2024년을 기준 연도, 2034년을 예측연도로 하여 2018-2034년 세계 키나아제 억제제 시장의 매출과 예측을 제공합니다. 또한 2024-2034년 세계 키나아제 억제제 시장의 연평균 성장률(CAGR%)을 제시합니다.

이 보고서는 광범위한 1차 연구를 통해 작성되었으며, 분석가들은 KOL(Key Opinion Leader), 업계 리더, 오피니언 제조업체를 인터뷰하고, 주요 기업의 제품 문서, 연례 보고서, 보도자료, 관련 문서 등을 참조하여 키나아제 억제제 시장을 추정했습니다. 억제제 시장을 추론했습니다.

시장 스냅숏
2023년 시장 규모	580억 9,010만 달러
2034년 시장 규모	899억 2,980만 달러
CAGR	3.9%

세계의 키나아제 저해제 시장의 경쟁 구도에 대해 조사하고 있습니다. 세계의 키나아제 저해제 시장에서 사업을 운영하는 주요 기업이 식별되고, 각 기업이 다양한 속성에서 프로파일링되고 있습니다. 기업 개요, 재무 상황, 최근 동향, SWOT가 이 리포트에서 소개되고 있는 세계의 키나아제 저해제 시장에서 플레이어의 속성입니다.

목차

제1장 서문

제2장 전제조건과 조사 방법

제3장 개요 : 세계 시장

제4장 시장 개요

• 서론
• 개요
• 시장 역학
• 세계의 시장 분석과 예측, 2020-2034년

제5장 주요 인사이트

• 주요 업계 이벤트
• PESTEL 분석
• 주요 국가·지역별 규제 시나리오
• Porter's Five Forces 분석
• 제품/브랜드 분석
• 공급망 분석
• 파이프라인 분석

제6장 세계의 시장 분석과 예측 : 유형별

• 서론과 정의
• 주요 조사 결과/진전
• 시장 금액 예측 : 유형별, 2020-2034년
  • 비수용체 티로신
    • BTK(Bruton's Tyrosine Kinase) 저해제
    • BCR-ABL
    • 야누스 키나아제(JAK) 저해제
    • 간엽계 상피 세포 전환 증식인자(c-MET)
    • 비장 티로신 키나아제(SYK) 저해제
    • 기타
  • 수용체 티로신
    • VEGFR
    • PDGFR
    • EGFR
    • 알크
    • 기타
  • 멀티
  • 세린/스레오닌
  • 프로테인 키나아제 C저해제
  • RHO
  • 기타
• 유형별 시장의 매력

제7장 세계의 시장 분석과 예측 : 투여 경로별

• 서론과 정의
• 주요 조사 결과/진전
• 시장 금액 예측 : 투여 경로별, 2020-2034년
  • 경구
  • 비경구제 및 기타
• 투여 경로별 시장의 매력

제8장 세계의 시장 분석과 예측 : 용도별

• 서론과 정의
• 주요 조사 결과/진전
• 시장 금액 예측 : 용도별, 2020-2034년
  • 종양학
    • 유방암
    • 백혈병
    • 신장암
    • 폐암
    • 흑색종
    • 대장암
    • 기타
  • 염증성 질환
  • 기타
• 용도별 시장의 매력

제9장 세계의 시장 분석과 예측 : 최종 용도별

• 서론과 정의
• 주요 조사 결과/진전
• 시장 금액 예측 : 최종 용도별, 2020-2034년
  • 병원 약국
  • 독립계 약국
  • 온라인 약국
• 최종 용도별 시장의 매력

제10장 세계의 시장 분석과 예측 : 지역별

• 주요 조사 결과
• 시장 금액 예측 : 지역별
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카
  • 중동 및 아프리카
• 지역별 시장의 매력

제11장 북미의 시장 분석과 예측

• 미국
• 캐나다

제12장 유럽의 시장 분석과 예측

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 기타 유럽 지역

제13장 아시아태평양의 시장 분석과 예측

• 중국
• 인도
• 일본
• 호주와 뉴질랜드
• 기타 아시아태평양

제14장 라틴아메리카의 시장 분석과 예측

• 브라질
• 멕시코
• 기타 라틴아메리카 지역

제15장 중동 및 아프리카의 시장 분석과 예측

• GCC 국가
• 남아프리카공화국
• 기타 중동 및 아프리카

제16장 경쟁 구도

• 시장 기업 - 경쟁 매트릭스(기업 계층별·규모별)
• 시장 점유율 분석 기업별(2023년)
• 기업 개요
  • Boehringer Ingelheim International GmbH
  • Novartis AG
  • AstraZeneca plc
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Johnson & Johnson Service, Inc.
  • Merck & Co., Inc.
  • Takeda Pharmaceuticals
  • Eisai Co., Ltd.
  • GSK Plc.
  • Eli Lilly
  • Alcon

KSA

영문 목차

영문목차

Kinase Inhibitors Market - Scope of Report

TMR's report on the global kinase inhibitors market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global kinase inhibitors market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global kinase inhibitors market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the kinase inhibitors market.

Market Snapshot
Market Value in 2023	US$ 58090.1 Mn
Market Value in 2034	US$ 89929.8 Mn
CAGR	3.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global kinase inhibitors market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global kinase inhibitors market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global kinase inhibitors market.

The report delves into the competitive landscape of the global kinase inhibitors market. Key players operating in the global kinase inhibitors market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global kinase inhibitors market profiled in this report.

Key Questions Answered in Global kinase inhibitors Market Report:

• What is the sales/revenue generated by kinase inhibitors across all regions during the forecast period?
• What are the opportunities in the global kinase inhibitors market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Kinase Inhibitors Market - Research Objectives and Research Approach

The comprehensive report on the global kinase inhibitors market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global kinase inhibitors market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global kinase inhibitors market.

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Kinase Inhibitors Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Kinase Inhibitors Market Analysis and Forecasts, 2020-2034
  • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

• 5.1. Key Industry Events
• 5.2. PESTEL Analysis
• 5.3. Regulatory Scenario by Key Countries/Regions
• 5.4. PORTER's Five Forces Analysis
• 5.5. Product/Brand Analysis
• 5.6. Supply Chain Analysis
• 5.7. Pipeline Analysis

6. Global Kinase Inhibitors Market Analysis and Forecasts, By Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Type, 2020-2034
  • 6.3.1. Non-receptor Tyrosine Kinase Inhibitors
    • 6.3.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 6.3.1.2. BCR-ABL
    • 6.3.1.3. Janus Kinase (JAK) Inhibitor
    • 6.3.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 6.3.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 6.3.1.6. Others
  • 6.3.2. Receptor Tyrosine Kinase Inhibitors
    • 6.3.2.1. VEGFR
    • 6.3.2.2. PDGFR
    • 6.3.2.3. EGFR
    • 6.3.2.4. ALK
    • 6.3.2.5. Others
  • 6.3.3. Multikinase Inhibitors
  • 6.3.4. Serine/Threonine Kinase Inhibitors
  • 6.3.5. Protein Kinase C Inhibitors
  • 6.3.6. RHO Kinase Inhibitors
  • 6.3.7. Others
• 6.4. Market Attractiveness By Type

7. Global Kinase Inhibitors Market Analysis and Forecasts, By Route of Administration

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Route of Administration, 2020-2034
  • 7.3.1. Oral
  • 7.3.2. Parenteral & Others
• 7.4. Market Attractiveness By Route of Administration

8. Global Kinase Inhibitors Market Analysis and Forecasts, By Application

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Application, 2020-2034
  • 8.3.1. Oncology
    • 8.3.1.1. Breast Cancer
    • 8.3.1.2. Leukemia
    • 8.3.1.3. Renal Cancers
    • 8.3.1.4. Lung Cancer
    • 8.3.1.5. Melanoma
    • 8.3.1.6. Colorectal Cancer
    • 8.3.1.7. Others
  • 8.3.2. Inflammatory Disorders
  • 8.3.3. Others
• 8.4. Market Attractiveness By Application

9. Global Kinase Inhibitors Market Analysis and Forecasts, By End-user

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By End-user, 2020-2034
  • 9.3.1. Hospital Pharmacies
  • 9.3.2. Independent Pharmacies
  • 9.3.3. Online Pharmacies
• 9.4. Market Attractiveness By End-user

10. Global Kinase Inhibitors Market Analysis and Forecasts, By Region

• 10.1. Key Findings
• 10.2. Market Value Forecast By Region
  • 10.2.1. North America
  • 10.2.2. Europe
  • 10.2.3. Asia Pacific
  • 10.2.4. Latin America
  • 10.2.5. Middle East & Africa
• 10.3. Market Attractiveness By Region

11. North America Kinase Inhibitors Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Type, 2020-2034
  • 11.2.1. Non-receptor Tyrosine Kinase Inhibitors
    • 11.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 11.2.1.2. BCR-ABL
    • 11.2.1.3. Janus Kinase (JAK) Inhibitor
    • 11.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 11.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 11.2.1.6. Others
  • 11.2.2. Receptor Tyrosine Kinase Inhibitors
    • 11.2.2.1. VEGFR
    • 11.2.2.2. PDGFR
    • 11.2.2.3. EGFR
    • 11.2.2.4. ALK
    • 11.2.2.5. Others
  • 11.2.3. Multikinase Inhibitors
  • 11.2.4. Serine/Threonine Kinase Inhibitors
  • 11.2.5. Protein Kinase C Inhibitors
  • 11.2.6. RHO Kinase Inhibitors
  • 11.2.7. Others
• 11.3. Market Value Forecast By Route of Administration, 2020-2034
  • 11.3.1. Oral
  • 11.3.2. Parenteral & Others
• 11.4. Market Value Forecast By Application, 2020-2034
  • 11.4.1. Oncology
    • 11.4.1.1. Breast Cancer
    • 11.4.1.2. Leukemia
    • 11.4.1.3. Renal Cancers
    • 11.4.1.4. Lung Cancer
    • 11.4.1.5. Melanoma
    • 11.4.1.6. Colorectal Cancer
    • 11.4.1.7. Others
  • 11.4.2. Inflammatory Disorders
  • 11.4.3. Others
• 11.5. Market Value Forecast By End-user, 2020-2034
  • 11.5.1. Hospital Pharmacies
  • 11.5.2. Independent Pharmacies
  • 11.5.3. Online Pharmacies
• 11.6. Market Value Forecast By Country, 2020-2034
  • 11.6.1. U.S.
  • 11.6.2. Canada
• 11.7. Market Attractiveness Analysis
  • 11.7.1. By Type
  • 11.7.2. By Route of Administration
  • 11.7.3. By Application
  • 11.7.4. By End-user
  • 11.7.5. By Country

12. Europe Kinase Inhibitors Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Type, 2020-2034
  • 12.2.1. Non-receptor Tyrosine Kinase Inhibitors
    • 12.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 12.2.1.2. BCR-ABL
    • 12.2.1.3. Janus Kinase (JAK) Inhibitor
    • 12.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 12.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 12.2.1.6. Others
  • 12.2.2. Receptor Tyrosine Kinase Inhibitors
    • 12.2.2.1. VEGFR
    • 12.2.2.2. PDGFR
    • 12.2.2.3. EGFR
    • 12.2.2.4. ALK
    • 12.2.2.5. Others
  • 12.2.3. Multikinase Inhibitors
  • 12.2.4. Serine/Threonine Kinase Inhibitors
  • 12.2.5. Protein Kinase C Inhibitors
  • 12.2.6. RHO Kinase Inhibitors
  • 12.2.7. Others
• 12.3. Market Value Forecast By Route of Administration, 2020-2034
  • 12.3.1. Oral
  • 12.3.2. Parenteral & Others
• 12.4. Market Value Forecast By Application, 2020-2034
  • 12.4.1. Oncology
    • 12.4.1.1. Breast Cancer
    • 12.4.1.2. Leukemia
    • 12.4.1.3. Renal Cancers
    • 12.4.1.4. Lung Cancer
    • 12.4.1.5. Melanoma
    • 12.4.1.6. Colorectal Cancer
    • 12.4.1.7. Others
  • 12.4.2. Inflammatory Disorders
  • 12.4.3. Others
• 12.5. Market Value Forecast By End-user, 2020-2034
  • 12.5.1. Hospital Pharmacies
  • 12.5.2. Independent Pharmacies
  • 12.5.3. Online Pharmacies
• 12.6. Market Value Forecast By Country/Sub-region, 2020-2034
  • 12.6.1. Germany
  • 12.6.2. U.K.
  • 12.6.3. France
  • 12.6.4. Italy
  • 12.6.5. Spain
  • 12.6.6. Rest of Europe
• 12.7. Market Attractiveness Analysis
  • 12.7.1. By Type
  • 12.7.2. By Route of Administration
  • 12.7.3. By Application
  • 12.7.4. By End-user
  • 12.7.5. By Country/Sub-region

13. Asia Pacific Kinase Inhibitors Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Type, 2020-2034
  • 13.2.1. Non-receptor Tyrosine Kinase Inhibitors
    • 13.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 13.2.1.2. BCR-ABL
    • 13.2.1.3. Janus Kinase (JAK) Inhibitor
    • 13.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 13.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 13.2.1.6. Others
  • 13.2.2. Receptor Tyrosine Kinase Inhibitors
    • 13.2.2.1. VEGFR
    • 13.2.2.2. PDGFR
    • 13.2.2.3. EGFR
    • 13.2.2.4. ALK
    • 13.2.2.5. Others
  • 13.2.3. Multikinase Inhibitors
  • 13.2.4. Serine/Threonine Kinase Inhibitors
  • 13.2.5. Protein Kinase C Inhibitors
  • 13.2.6. RHO Kinase Inhibitors
  • 13.2.7. Others
• 13.3. Market Value Forecast By Route of Administration, 2020-2034
  • 13.3.1. Oral
  • 13.3.2. Parenteral & Others
• 13.4. Market Value Forecast By Application, 2020-2034
  • 13.4.1. Oncology
    • 13.4.1.1. Breast Cancer
    • 13.4.1.2. Leukemia
    • 13.4.1.3. Renal Cancers
    • 13.4.1.4. Lung Cancer
    • 13.4.1.5. Melanoma
    • 13.4.1.6. Colorectal Cancer
    • 13.4.1.7. Others
  • 13.4.2. Inflammatory Disorders
  • 13.4.3. Others
• 13.5. Market Value Forecast By End-user, 2020-2034
  • 13.5.1. Hospital Pharmacies
  • 13.5.2. Independent Pharmacies
  • 13.5.3. Online Pharmacies
• 13.6. Market Value Forecast By Country/Sub-region, 2020-2034
  • 13.6.1. China
  • 13.6.2. India
  • 13.6.3. Japan
  • 13.6.4. Australia & New Zealand
  • 13.6.5. Rest of Asia Pacific
• 13.7. Market Attractiveness Analysis
  • 13.7.1. By Type
  • 13.7.2. By Route of Administration
  • 13.7.3. By Application
  • 13.7.4. By End-user
  • 13.7.5. By Country/Sub-region

14. Latin America Kinase Inhibitors Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Type, 2020-2034
  • 14.2.1. Non-receptor Tyrosine Kinase Inhibitors
    • 14.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 14.2.1.2. BCR-ABL
    • 14.2.1.3. Janus Kinase (JAK) Inhibitor
    • 14.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 14.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 14.2.1.6. Others
  • 14.2.2. Receptor Tyrosine Kinase Inhibitors
    • 14.2.2.1. VEGFR
    • 14.2.2.2. PDGFR
    • 14.2.2.3. EGFR
    • 14.2.2.4. ALK
    • 14.2.2.5. Others
  • 14.2.3. Multikinase Inhibitors
  • 14.2.4. Serine/Threonine Kinase Inhibitors
  • 14.2.5. Protein Kinase C Inhibitors
  • 14.2.6. RHO Kinase Inhibitors
  • 14.2.7. Others
• 14.3. Market Value Forecast By Route of Administration, 2020-2034
  • 14.3.1. Oral
  • 14.3.2. Parenteral & Others
• 14.4. Market Value Forecast By Application, 2020-2034
  • 14.4.1. Oncology
    • 14.4.1.1. Breast Cancer
    • 14.4.1.2. Leukemia
    • 14.4.1.3. Renal Cancers
    • 14.4.1.4. Lung Cancer
    • 14.4.1.5. Melanoma
    • 14.4.1.6. Colorectal Cancer
    • 14.4.1.7. Others
  • 14.4.2. Inflammatory Disorders
  • 14.4.3. Others
• 14.5. Market Value Forecast By End-user, 2020-2034
  • 14.5.1. Hospital Pharmacies
  • 14.5.2. Independent Pharmacies
  • 14.5.3. Online Pharmacies
• 14.6. Market Value Forecast By Country/Sub-region, 2020-2034
  • 14.6.1. Brazil
  • 14.6.2. Mexico
  • 14.6.3. Rest of Latin America
• 14.7. Market Attractiveness Analysis
  • 14.7.1. By Type
  • 14.7.2. By Route of Administration
  • 14.7.3. By Application
  • 14.7.4. By End-user
  • 14.7.5. By Country/Sub-region

15. Middle East & Africa Kinase Inhibitors Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Type, 2020-2034
  • 15.2.1. Non-receptor Tyrosine Kinase Inhibitors
    • 15.2.1.1. Bruton's Tyrosine Kinase (BTK) Inhibitors
    • 15.2.1.2. BCR-ABL
    • 15.2.1.3. Janus Kinase (JAK) Inhibitor
    • 15.2.1.4. Mesenchymal Epithelial Transition Growth Factor (c-MET)
    • 15.2.1.5. Spleen Tyrosine Kinase (SYK) Inhibitors
    • 15.2.1.6. Others
  • 15.2.2. Receptor Tyrosine Kinase Inhibitors
    • 15.2.2.1. VEGFR
    • 15.2.2.2. PDGFR
    • 15.2.2.3. EGFR
    • 15.2.2.4. ALK
    • 15.2.2.5. Others
  • 15.2.3. Multikinase Inhibitors
  • 15.2.4. Serine/Threonine Kinase Inhibitors
  • 15.2.5. Protein Kinase C Inhibitors
  • 15.2.6. RHO Kinase Inhibitors
  • 15.2.7. Others
• 15.3. Market Value Forecast By Route of Administration, 2020-2034
  • 15.3.1. Oral
  • 15.3.2. Parenteral & Others
• 15.4. Market Value Forecast By Application, 2020-2034
  • 15.4.1. Oncology
    • 15.4.1.1. Breast Cancer
    • 15.4.1.2. Leukemia
    • 15.4.1.3. Renal Cancers
    • 15.4.1.4. Lung Cancer
    • 15.4.1.5. Melanoma
    • 15.4.1.6. Colorectal Cancer
    • 15.4.1.7. Others
  • 15.4.2. Inflammatory Disorders
  • 15.4.3. Others
• 15.5. Market Value Forecast By End-user, 2020-2034
  • 15.5.1. Hospital Pharmacies
  • 15.5.2. Independent Pharmacies
  • 15.5.3. Online Pharmacies
• 15.6. Market Value Forecast By Country/Sub-region, 2020-2034
  • 15.6.1. GCC Countries
  • 15.6.2. South Africa
  • 15.6.3. Rest of Middle East & Africa
• 15.7. Market Attractiveness Analysis
  • 15.7.1. By Type
  • 15.7.2. By Route of Administration
  • 15.7.3. By Application
  • 15.7.4. By End-user
  • 15.7.5. By Country/Sub-region

16. Competition Landscape

• 16.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 16.2. Market Share Analysis By Company (2023)
• 16.3. Company Profiles
  • 16.3.1. Boehringer Ingelheim International GmbH
    • 16.3.1.1. Company Overview
    • 16.3.1.2. Financial Overview
    • 16.3.1.3. Product Portfolio
    • 16.3.1.4. Business Strategies
    • 16.3.1.5. Recent Developments
  • 16.3.2. Novartis AG
    • 16.3.2.1. Company Overview
    • 16.3.2.2. Financial Overview
    • 16.3.2.3. Product Portfolio
    • 16.3.2.4. Business Strategies
    • 16.3.2.5. Recent Developments
  • 16.3.3. AstraZeneca plc
    • 16.3.3.1. Company Overview
    • 16.3.3.2. Financial Overview
    • 16.3.3.3. Product Portfolio
    • 16.3.3.4. Business Strategies
    • 16.3.3.5. Recent Developments
  • 16.3.4. Pfizer, Inc.
    • 16.3.4.1. Company Overview
    • 16.3.4.2. Financial Overview
    • 16.3.4.3. Product Portfolio
    • 16.3.4.4. Business Strategies
    • 16.3.4.5. Recent Developments
  • 16.3.5. F. Hoffmann-La Roche Ltd
    • 16.3.5.1. Company Overview
    • 16.3.5.2. Financial Overview
    • 16.3.5.3. Product Portfolio
    • 16.3.5.4. Business Strategies
    • 16.3.5.5. Recent Developments
  • 16.3.6. Bristol-Myers Squibb Company
    • 16.3.6.1. Company Overview
    • 16.3.6.2. Financial Overview
    • 16.3.6.3. Product Portfolio
    • 16.3.6.4. Business Strategies
    • 16.3.6.5. Recent Developments
  • 16.3.7. Bayer AG
    • 16.3.7.1. Company Overview
    • 16.3.7.2. Financial Overview
    • 16.3.7.3. Product Portfolio
    • 16.3.7.4. Business Strategies
    • 16.3.7.5. Recent Developments
  • 16.3.8. Johnson & Johnson Service, Inc.
    • 16.3.8.1. Company Overview
    • 16.3.8.2. Financial Overview
    • 16.3.8.3. Product Portfolio
    • 16.3.8.4. Business Strategies
    • 16.3.8.5. Recent Developments
  • 16.3.9. Merck & Co., Inc.
    • 16.3.9.1. Company Overview
    • 16.3.9.2. Financial Overview
    • 16.3.9.3. Product Portfolio
    • 16.3.9.4. Business Strategies
    • 16.3.9.5. Recent Developments
  • 16.3.10. Takeda Pharmaceuticals
    • 16.3.10.1. Company Overview
    • 16.3.10.2. Financial Overview
    • 16.3.10.3. Product Portfolio
    • 16.3.10.4. Business Strategies
    • 16.3.10.5. Recent Developments
  • 16.3.11. Eisai Co., Ltd.
    • 16.3.11.1. Company Overview
    • 16.3.11.2. Financial Overview
    • 16.3.11.3. Product Portfolio
    • 16.3.11.4. Business Strategies
    • 16.3.11.5. Recent Developments
  • 16.3.12. GSK Plc.
    • 16.3.12.1. Company Overview
    • 16.3.12.2. Financial Overview
    • 16.3.12.3. Product Portfolio
    • 16.3.12.4. Business Strategies
    • 16.3.12.5. Recent Developments
  • 16.3.13. Eli Lilly
    • 16.3.13.1. Company Overview
    • 16.3.13.2. Financial Overview
    • 16.3.13.3. Product Portfolio
    • 16.3.13.4. Business Strategies
    • 16.3.13.5. Recent Developments
  • 16.3.14. Alcon
    • 16.3.14.1. Company Overview
    • 16.3.14.2. Financial Overview
    • 16.3.14.3. Product Portfolio
    • 16.3.14.4. Business Strategies
    • 16.3.14.5. Recent Developments

관련자료